Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1987 1
1988 1
1991 2
1994 1
1996 1
1999 1
2001 2
2004 2
2005 2
2006 2
2009 1
2010 1
2011 1
2012 3
2013 1
2014 1
2015 1
2016 2
2017 1
2018 1
2019 1
2020 1
2021 1
2022 1
2023 4
2024 1

Text availability

Article attribute

Article type

Publication date

Search Results

34 results

Results by year

Filters applied: . Clear all
Page 1
Treatment of lung large cell neuroendocrine carcinoma.
Lo Russo G, Pusceddu S, Proto C, Macerelli M, Signorelli D, Vitali M, Ganzinelli M, Gallucci R, Zilembo N, Platania M, Buzzoni R, de Braud F, Garassino MC. Lo Russo G, et al. Tumour Biol. 2016 Jun;37(6):7047-57. doi: 10.1007/s13277-016-5003-4. Epub 2016 Mar 4. Tumour Biol. 2016. PMID: 26943800 Review.
Most of the available data related to its treatment derive from retrospective analyses or small case series. For patients with L-LCNEC, prognosis is generally very poor. In early stages (I-II-III), surgery is recommended but does not seem to be sufficient. ...
Most of the available data related to its treatment derive from retrospective analyses or small case series. For patients with L-LCNEC, p …
Whole-exome and targeted gene sequencing of large-cell lung carcinoma reveals recurrent mutations in the PI3K pathway.
Guo JH, Ma YS, Lin JW, Jiang GX, He J, Lu HM, Wu W, Diao X, Fan QY, Wu CY, Liu JB, Fu D, Hou LK. Guo JH, et al. Br J Cancer. 2023 Aug;129(2):366-373. doi: 10.1038/s41416-023-02301-2. Epub 2023 May 13. Br J Cancer. 2023. PMID: 37179440 Free PMC article.
BACKGROUND: Large cell lung carcinoma (LCLC) is an exceptionally aggressive disease with a poor prognosis. At present, little is known about the molecular pathology of LCLC. ...Multivariate analysis further revealed that patients with the PI3K signaling pathway mutations h …
BACKGROUND: Large cell lung carcinoma (LCLC) is an exceptionally aggressive disease with a poor prognosis. At present, little is know …
SMARCA4 deficiency and mutations are frequent in large cell lung carcinoma and are prognostically significant.
Cheung AH, Wong KY, Chau SL, Xie F, Mui Z, Li GY, Li MSC, Tong J, Ng CS, Mok TS, Kang W, To KF. Cheung AH, et al. Pathology. 2024 Jun;56(4):504-515. doi: 10.1016/j.pathol.2023.12.414. Epub 2024 Feb 15. Pathology. 2024. PMID: 38413251
SMARCA4 mutation has emerged as a marker of poor prognosis in lung cancer and has potential predictive value in cancer treatment, but recommendations for which patients require its investigation are lacking. ...SMARCA4 mutation or its deficiency was associated with …
SMARCA4 mutation has emerged as a marker of poor prognosis in lung cancer and has potential predictive value in cancer treatme …
Mixed squamous and large-cell carcinoma of the lung: a case study and literature review.
Katsenos S, Karachaliou I, Archondakis S. Katsenos S, et al. J Cancer Res Ther. 2012 Jul-Sep;8(3):445-7. doi: 10.4103/0973-1482.103531. J Cancer Res Ther. 2012. PMID: 23174733 Free article. Review.
A brief review of the current literature is also included with special emphasis on the clinicopathologic aspects and prognosis of lung tumors with mixed histology....
A brief review of the current literature is also included with special emphasis on the clinicopathologic aspects and prognosis of lun …
Prevalence and clinical significance of RBM3 immunostaining in non-small cell lung cancers.
Melling N, Bachmann K, Hofmann B, El Gammal AT, Reeh M, Mann O, Moebius C, Blessmann M, Izbicki JR, Grupp K. Melling N, et al. J Cancer Res Clin Oncol. 2019 Apr;145(4):873-879. doi: 10.1007/s00432-019-02850-1. Epub 2019 Feb 13. J Cancer Res Clin Oncol. 2019. PMID: 30758670
INTRODUCTION: Aberrant expression of RNA-binding motif protein 3 (RBM3) has been suggested as a prognostic biomarker in several malignancies. MATERIALS AND METHODS: This study was performed to analyse the prevalence and clinical significance of RBM3 immunostaining in non-s …
INTRODUCTION: Aberrant expression of RNA-binding motif protein 3 (RBM3) has been suggested as a prognostic biomarker in several malig …
Effect of Chemotherapy in Stage II-IV Large-Cell Lung Carcinoma and Construction of Its Predictive Nomograms: A SEER Analysis.
Hu G, Liu Y, Li X, Jin M, Liu X, Yu Q. Hu G, et al. Med Princ Pract. 2023;32(1):49-60. doi: 10.1159/000529202. Epub 2023 Jan 18. Med Princ Pract. 2023. PMID: 36652925 Free PMC article.
OBJECTIVES: Large-cell lung carcinoma (LCLC) is generally poorly differentiated with a poor prognosis. This study aimed to explore the impact of chemotherapy on the prognosis of patients with stage II-IV LCLC and to construct nomograms to predict overall surv …
OBJECTIVES: Large-cell lung carcinoma (LCLC) is generally poorly differentiated with a poor prognosis. This study aimed to explore th …
RAI3 expression is not associated with clinical outcomes of patients with non-small cell lung cancer.
Melling N, Reeh M, Ghadban T, Tachezy M, Hajek A, Izbicki JR, Grupp K. Melling N, et al. J Cancer Res Clin Oncol. 2023 Aug;149(9):6549-6555. doi: 10.1007/s00432-023-04631-3. Epub 2023 Feb 13. J Cancer Res Clin Oncol. 2023. PMID: 36781501 Free PMC article.
PURPOSE: Retinoic acid inducible protein 3 (RAI3) has been suggested as prognostic biomarker in several cancer types. The present study aimed to examine the role of RAI3 expression in non-small cell lung cancers (NSCLCs). ...CONCLUSION: Our study shows that RAI3 expression …
PURPOSE: Retinoic acid inducible protein 3 (RAI3) has been suggested as prognostic biomarker in several cancer types. The present stu …
Clinicopathological analysis of Large Cell Lung Carcinomas definitely diagnosed according to the New World Health Organization Criteria.
Bi Y, Qu Y, Liang Z, Liu Z, Zhang H, Liang X, Luo Y, Cao J, Zhang H, Feng R. Bi Y, et al. Pathol Res Pract. 2018 Apr;214(4):555-559. doi: 10.1016/j.prp.2018.02.006. Epub 2018 Feb 14. Pathol Res Pract. 2018. PMID: 29525405
The 3-year overall survival rate was 48.4 15.1%. Chemotherapy was the only predictive factor that is associated with the prognosis of the patients (P = 0.003). ...LCC in our study showed aggressive behavior with high recurrence and metastasis and poor prognosis …
The 3-year overall survival rate was 48.4 15.1%. Chemotherapy was the only predictive factor that is associated with the prognosis …
Case Report: Therapeutic Response to Chemo-Immunotherapy in an Advanced Large Cell Lung Carcinoma Patient With Low Values of Multiple Predictive Biomarkers.
Wang G, Chai Q, Xiao Y, Peng W, Teng M, Wang J, Lin H, Su X, Wu L. Wang G, et al. Front Immunol. 2021 Jan 28;11:607416. doi: 10.3389/fimmu.2020.607416. eCollection 2020. Front Immunol. 2021. PMID: 33584678 Free PMC article.
Immune checkpoint inhibitors have revolutionized the treatments of lung cancers, and multiple predictive biomarkers alone or in combination help clinicians with the appropriate therapeutic selections. ...This case suggests that chemo-immunotherapy may provide an effective …
Immune checkpoint inhibitors have revolutionized the treatments of lung cancers, and multiple predictive biomarkers alone or in combi …
34 results